274 related articles for article (PubMed ID: 19382087)
1. [Reliability of administrative databases in epidemiological research: the example of end-stage renal disease requiring renal replacement therapy in patients with diabetes].
Nordio M; Antonucci F; Feriani M; Inio A; Marchini P
G Ital Nefrol; 2009; 26 Suppl 45():S7-11. PubMed ID: 19382087
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
3. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
4. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
5. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
6. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
[TBL] [Abstract][Full Text] [Related]
7. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of administrative databases for identifying disease cohorts is increased with a multivariate model.
van Walraven C; Austin PC; Manuel D; Knoll G; Jennings A; Forster AJ
J Clin Epidemiol; 2010 Dec; 63(12):1332-41. PubMed ID: 20457509
[TBL] [Abstract][Full Text] [Related]
9. Renal replacement therapy for diabetic end-stage renal disease. Experience of a Tunisian hospital centre.
Abderrahim E; Zouaghi K; Hedri H; Ben Abdallah T; Ben Hamida F; Kaaroud H; Goucha R; Ben Abdallah N; Khiari K; El Younsi F; Ben Moussa F; Kheder A; Ben Maïz H
Diabetes Metab; 2001 Nov; 27(5 Pt 1):584-90. PubMed ID: 11694858
[TBL] [Abstract][Full Text] [Related]
10. Optimizing end-stage renal disease therapy for the patient with diabetes mellitus.
Friedlander MA; Hricik DE
Semin Nephrol; 1997 Jul; 17(4):331-45. PubMed ID: 9241718
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of end-stage renal disease in an interregional perspective: Registries of Puglia and Basilicata, southern Italy.
Vitullo F; Casino FG; Di Matteo A; Di Candia VD; Gaudiano V; Piras V; Alfonso L; Basile C; Procaccini DA; Gesualdo L;
J Nephrol; 2003; 16(6):813-21. PubMed ID: 14736008
[TBL] [Abstract][Full Text] [Related]
12. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
13. The effect of diabetes on incidence and mortality in end-stage renal disease in Germany.
Hoffmann F; Haastert B; Koch M; Giani G; Glaeske G; Icks A
Nephrol Dial Transplant; 2011 May; 26(5):1634-40. PubMed ID: 20959344
[TBL] [Abstract][Full Text] [Related]
14. Duration of end-stage renal disease and kidney transplant outcome.
Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
[TBL] [Abstract][Full Text] [Related]
15. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients.
Hattori S; Yosioka K; Honda M; Ito H;
Pediatr Nephrol; 2002 Jun; 17(6):456-61. PubMed ID: 12107812
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of patients after kidney transplantation: a comparison of those with or without diabetes mellitus.
Schiel R; Heinrich S; Steiner T; Ott U; Stein G
Nephrol Dial Transplant; 2005 Mar; 20(3):611-7. PubMed ID: 15689368
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
18. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
19. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease.
Tiwari A; Tseng CL; Kern EF; Maney M; Miller DR; Pogach L
Am J Manag Care; 2007 Feb; 13(2):73-9. PubMed ID: 17286527
[TBL] [Abstract][Full Text] [Related]
20. Use of a state data bank to measure incidence and prevalence of a chronic disease: end-stage renal failure.
Brameld K; Holman D; Thomas M; Bass J
Am J Kidney Dis; 1999 Dec; 34(6):1033-9. PubMed ID: 10585312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
